Figure 1.
Overall survival, disease-free survival, freedom from distant metastases, and local control from the National Cancer Institute #5642 study (bevacizumab group). Shown are Kaplan–Meier estimates of disease-free survival (A), overall survival (B), freedom from distant metastases (C), and local control (D).